

Joseph S. Ross

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6806430/publications.pdf>

Version: 2024-02-01

152
papers

11,234
citations

53660

45
h-index

30848

102
g-index

165
all docs

165
docs citations

165
times ranked

13574
citing authors

#	ARTICLE	IF	CITATIONS
1	Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020. <i>Journal of General Internal Medicine</i> , 2022, 37, 700-702.	1.3	2
2	Clinical studies sponsored by digital health companies participating in the FDA’s Precertification Pilot Program: A cross-sectional analysis. <i>Clinical Trials</i> , 2022, 19, 119-122.	0.7	2
3	Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adults. <i>Endocrine</i> , 2022, 76, 349-358.	1.1	2
4	A multicenter evaluation of computable phenotyping approaches for SARS-CoV-2 infection and COVID-19 hospitalizations. <i>Npj Digital Medicine</i> , 2022, 5, 27.	5.7	9
5	Medical Device User Fee Reauthorization – Back to Basics or Looking Ahead?. <i>New England Journal of Medicine</i> , 2022, 387, 196-199.	13.9	2
6	Medicare’s New Device-Coverage Pathway – Breakthrough or Breakdown?. <i>New England Journal of Medicine</i> , 2021, 384, e43.	13.9	9
7	US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018. <i>Clinical Trials</i> , 2021, 18, 488-499.	0.7	13
8	Leveraging Open Science to Accelerate Research. <i>New England Journal of Medicine</i> , 2021, 384, e61.	13.9	22
9	Direct-to-consumer personal genomic tests need better regulation. <i>Nature Medicine</i> , 2021, 27, 940-943.	15.2	7
10	Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use. <i>Endocrine</i> , 2021, 74, 592-602.	1.1	2
11	Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation. <i>Clinical Trials</i> , 2021, 18, 174077452110306.	0.7	1
12	Characteristics of available studies and dissemination of research using major clinical data sharing platforms. <i>Clinical Trials</i> , 2021, 18, 657-666.	0.7	18
13	Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008040.	0.9	0
14	Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA. <i>Trials</i> , 2021, 22, 817.	0.7	4
15	Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics. <i>Journal of General Internal Medicine</i> , 2020, 35, 1928-1930.	1.3	5
16	Confidentiality Orders and Public Interest in Drug and Medical Device Litigation. <i>JAMA Internal Medicine</i> , 2020, 180, 292.	2.6	4
17	Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA. <i>Trials</i> , 2020, 21, 675.	0.7	18
18	Early experience with the FDA’s Breakthrough Devices program. <i>Nature Biotechnology</i> , 2020, 38, 933-938.	9.4	20

#	ARTICLE	IF	CITATIONS
19	Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials. <i>Clinical Trials</i> , 2020, 17, 723-728.	0.7	0
20	Assessment of Preprint Policies of Top-Ranked Clinical Journals. <i>JAMA Network Open</i> , 2020, 3, e2011127.	2.8	36
21	Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 734.	3.8	260
22	Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. <i>Journal of the American Heart Association</i> , 2020, 9, e013606.	1.6	10
23	Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. <i>Thrombosis Research</i> , 2020, 186, 78-79.	0.8	2
24	Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform. <i>Npj Digital Medicine</i> , 2020, 3, 60.	5.7	51
25	Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trials—a brave new world. <i>Clinical Trials</i> , 2020, 17, 243-246.	0.7	2
26	Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. <i>JAMA Network Open</i> , 2020, 3, e203284.	2.8	58
27	Time for NIH to lead on data sharing. <i>Science</i> , 2020, 367, 1308-1309.	6.0	42
28	Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measures. <i>PLoS ONE</i> , 2020, 15, e0230734.	1.1	1
29	Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008–2015. <i>Milbank Quarterly</i> , 2019, 97, 796-819.	2.1	17
30	Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies. <i>Journal of General Internal Medicine</i> , 2019, 34, 2319-2321.	1.3	4
31	Modernizing the FDA’s 510(k) Pathway. <i>New England Journal of Medicine</i> , 2019, 381, 1891-1893.	13.9	23
32	Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals. <i>Circulation</i> , 2019, 140, 379-389.	1.6	24
33	Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2305-2314.	1.8	24
34	Association Between Insurance Status and Access to Hospital Care in Emergency Department Disposition. <i>JAMA Internal Medicine</i> , 2019, 179, 686.	2.6	41
35	Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation. <i>BMJ Open</i> , 2019, 9, e025936.	0.8	0
36	Digital medicine systems: an evergreening strategy or an advance in medication management?. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 203-204.	1.7	4

#	ARTICLE	IF	CITATIONS
37	Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017. <i>Research Integrity and Peer Review</i> , 2019, 4, 26.	2.2	1
38	Generic Drugs in the United States: Policies to Address Pricing and Competition. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 329-337.	2.3	27
39	Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. <i>JAMA Internal Medicine</i> , 2019, 179, 263.	2.6	9
40	Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines. <i>Journal of General Internal Medicine</i> , 2018, 33, 651-658.	1.3	20
41	Defining Multiple Chronic Conditions for Quality Measurement. <i>Medical Care</i> , 2018, 56, 193-201.	1.1	14
42	Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes. <i>Annals of the American Thoracic Society</i> , 2018, 15, 562-569.	1.5	27
43	The Impact of Off-Patent Drug Acquisitions on Prices. <i>Journal of General Internal Medicine</i> , 2018, 33, 1007-1009.	1.3	2
44	New and incremental FDA black box warnings from 2008 to 2015. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 117-123.	1.0	21
45	Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population. <i>BMJ Open</i> , 2018, 8, e021685.	0.8	3
46	Emergency Department Volume and Outcomes for Patients After Chest Pain Assessment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004683.	0.9	22
47	Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. <i>Trials</i> , 2018, 19, 581.	0.7	24
48	Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia. <i>JAMA Network Open</i> , 2018, 1, e182044.	2.8	42
49	Fulfilling the Promise of Unique Device Identifiers. <i>Annals of Internal Medicine</i> , 2018, 169, 183.	2.0	18
50	Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 848-856.	0.9	1
51	Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators. <i>Annals of Internal Medicine</i> , 2018, 169, 586.	2.0	12
52	Patterns and predictors of off-label prescription of psychiatric drugs. <i>PLoS ONE</i> , 2018, 13, e0198363.	1.1	40
53	Age of Data at the Time of Publication of Contemporary Clinical Trials. <i>JAMA Network Open</i> , 2018, 1, e181065.	2.8	23
54	Overview and experience of the YODA Project with clinical trial data sharing after 5 years. <i>Scientific Data</i> , 2018, 5, 180268.	2.4	48

#	ARTICLE	IF	CITATIONS
55	Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1854.	3.8	235
56	Hospital Characteristics Associated With Risk-standardized Readmission Rates. <i>Medical Care</i> , 2017, 55, 528-534.	1.1	48
57	Having Their Cake and Eating It Too: Physician Skepticism of the Open Payments Program. <i>American Journal of Bioethics</i> , 2017, 17, 19-22.	0.5	2
58	Regulatory Review of New Therapeutic Agents – FDA versus EMA, 2011–2015. <i>New England Journal of Medicine</i> , 2017, 376, 1386-1387.	13.9	47
59	Merits of Data Sharing. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1825-1827.	1.2	8
60	Hospital-Readmission Risk – Isolating Hospital Effects from Patient Effects. <i>New England Journal of Medicine</i> , 2017, 377, 1055-1064.	13.9	93
61	Quality of Care in the United States Territories, 1999–2012. <i>Medical Care</i> , 2017, 55, 886-892.	1.1	4
62	Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 270.	3.8	176
63	Data Sharing and Cardiology. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3018-3025.	1.2	11
64	Regulatory Review of New Therapeutic Agents. <i>New England Journal of Medicine</i> , 2017, 376, 2598-2598.	13.9	10
65	Data Desert for Inferior Vena Caval Filters. <i>JAMA Cardiology</i> , 2017, 2, 3.	3.0	14
66	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. <i>Diabetes Care</i> , 2017, 40, 468-475.	4.3	249
67	A Nationwide Assessment of the Association of Smoking Bans and Cigarette Taxes With Hospitalizations for Acute Myocardial Infarction, Heart Failure, and Pneumonia. <i>Medical Care Research and Review</i> , 2017, 74, 687-704.	1.0	14
68	US drug marketing: how does promotion correspond with health value?. <i>BMJ: British Medical Journal</i> , 2017, 357, j1855.	2.4	36
69	Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. <i>Trials</i> , 2017, 18, 333.	0.7	43
70	Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979–2015. <i>Ophthalmology</i> , 2017, 124, 1237-1246.	2.5	2
71	Risk-standardized Acute Admission Rates Among Patients With Diabetes and Heart Failure as a Measure of Quality of Accountable Care Organizations. <i>Medical Care</i> , 2016, 54, 528-537.	1.1	15
72	Commentary: Diagnostic devices in clinical trials have high stakes for patient care. <i>BMJ, The</i> , 2016, 354, i5197.	3.0	1

#	ARTICLE	IF	CITATIONS
73	Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2647.	3.8	230
74	Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation. <i>Annals of Internal Medicine</i> , 2016, 165, 20.	2.0	64
75	Comparative Effectiveness of Generic Atorvastatin and Lipitor [®] in Patients Hospitalized with an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2016, 5, e003350.	1.6	29
76	Clinical research data sharing: what an open science world means for researchers involved in evidence synthesis. <i>Systematic Reviews</i> , 2016, 5, 159.	2.5	22
77	Characterisation of trials where marketing purposes have been influential in study design: a descriptive study. <i>Trials</i> , 2016, 17, 31.	0.7	28
78	Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals. <i>Trials</i> , 2016, 17, 199.	0.7	66
79	Availability of Clinical Trial Data From Industry-Sponsored Cardiovascular Trials. <i>Journal of the American Heart Association</i> , 2016, 5, e003307.	1.6	15
80	Association of Admission to Veterans Affairs Hospitals vs Non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 582.	3.8	90
81	Development and Validation of an Algorithm to Identify Planned Readmissions From Claims Data. <i>Journal of Hospital Medicine</i> , 2015, 10, 670-677.	0.7	52
82	National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE) Retrospective AMI Study, 2001, 2006, and 2011. <i>Journal of the American Heart Association</i> , 2015, 4, e001718.	1.6	7
83	Decision-making and cancer screening: A qualitative study of older adults with multiple chronic conditions. <i>Journal of Geriatric Oncology</i> , 2015, 6, 93-100.	0.5	22
84	Efficacy And Safety Concerns Are Important Reasons Why The FDA Requires Multiple Reviews Before Approval Of New Drugs. <i>Health Affairs</i> , 2015, 34, 681-688.	2.5	15
85	Poorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007. <i>Circulation</i> , 2015, 131, 1755-1762.	1.6	30
86	Variation in US Hospital Emergency Department Admission Rates by Clinical Condition. <i>Medical Care</i> , 2015, 53, 237-244.	1.1	78
87	Characterizing the US FDA's approach to promoting transformative innovation. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 740-741.	21.5	10
88	On Ghosts and Other Unwelcome Guests. <i>Journal of General Internal Medicine</i> , 2015, 30, 1389-1391.	1.3	2
89	Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 604.	3.8	87
90	Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional survey. <i>Trials</i> , 2014, 15, 384.	0.7	24

#	ARTICLE	IF	CITATIONS
91	Moving Forward From rhBMP-2. <i>Spine</i> , 2014, 39, 531-532.	1.0	1
92	Reporting of Results in ClinicalTrials.gov and High-Impact Journals. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1063.	3.8	87
93	Place of Residence and Outcomes of Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 749-756.	0.9	53
94	Sea Change in Open Science and Data Sharing. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 499-504.	0.9	43
95	Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 368.	3.8	327
96	National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011. <i>JAMA Internal Medicine</i> , 2014, 174, 1116.	2.6	324
97	Trends in Use of Ezetimibe After the ENHANCE Trial, 2007 Through 2010. <i>JAMA Internal Medicine</i> , 2014, 174, 1486.	2.6	20
98	Payments for Acute Myocardial Infarction Episodes-of-Care Initiated at Hospitals With and Without Interventional Capabilities. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 882-888.	0.9	4
99	Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature. <i>JAMA Internal Medicine</i> , 2014, 174, 1176.	2.6	12
100	Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada. <i>American Heart Journal</i> , 2014, 167, 683-689.	1.2	16
101	Usual Source of Care and Outcomes Following Acute Myocardial Infarction. <i>Journal of General Internal Medicine</i> , 2014, 29, 862-869.	1.3	16
102	Impact of Drug Policy on Regional Trends in Ezetimibe Use. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 589-596.	0.9	8
103	Physician clinical management strategies and reasoning: a cross-sectional survey using clinical vignettes of eight common medical admissions. <i>BMC Health Services Research</i> , 2014, 14, 176.	0.9	5
104	Hospital variation in risk-standardized hospital admission rates from US EDs among adults. <i>American Journal of Emergency Medicine</i> , 2014, 32, 837-843.	0.7	25
105	Transfer Rates From Nonprocedure Hospitals After Initial Admission and Outcomes Among Elderly Patients With Acute Myocardial Infarction. <i>JAMA Internal Medicine</i> , 2014, 174, 213.	2.6	17
106	Direct-to-Consumer Television Advertising: Time to Turn Off the Tube?. <i>Journal of General Internal Medicine</i> , 2013, 28, 862-864.	1.3	5
107	Hospital-Based, Acute Care Use Among Patients Within 30 Days of Discharge After Coronary Artery Bypass Surgery. <i>Annals of Thoracic Surgery</i> , 2013, 96, 96-104.	0.7	37
108	Ushering in a New Era of Open Science Through Data Sharing. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1355.	3.8	106

#	ARTICLE	IF	CITATIONS
109	When Choosing Statin Therapy. JAMA Internal Medicine, 2013, 173, 229.	2.6	20
110	Regional Density of Cardiologists and Rates of Mortality for Acute Myocardial Infarction and Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 352-359.	0.9	29
111	Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia. JAMA - Journal of the American Medical Association, 2013, 309, 355.	3.8	831
112	Relationship Between Hospital Readmission and Mortality Rates for Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. JAMA - Journal of the American Medical Association, 2013, 309, 587.	3.8	307
113	A Historic Moment for Open Science: The Yale University Open Data Access Project and Medtronic. Annals of Internal Medicine, 2013, 158, 910.	2.0	59
114	Time to Publication Among Completed Clinical Trials. JAMA Internal Medicine, 2013, 173, 825.	2.6	92
115	Coronary Artery Bypass Graft. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 214-221.	0.9	21
116	Based On Key Measures, Care Quality For Medicare Enrollees At Safety-Net And Non-Safety-Net Hospitals Was Almost Equal. Health Affairs, 2012, 31, 1739-1748.	2.5	45
117	The Importance of Clinical Trial Data Sharing. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 238-240.	0.9	83
118	State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning. Health Affairs, 2012, 31, 188-198.	2.5	13
119	Generic Atorvastatin and Health Care Costs. New England Journal of Medicine, 2012, 366, 201-204.	13.9	56
120	Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ: British Medical Journal, 2012, 344, d7292-d7292.	2.4	318
121	Financial Stress and Outcomes after Acute Myocardial Infarction. PLoS ONE, 2012, 7, e47420.	1.1	28
122	Regulatory Review of Novel Therapeutics â€” Comparison of Three Regulatory Agencies. New England Journal of Medicine, 2012, 366, 2284-2293.	13.9	146
123	Promoting Transparency in Pharmaceutical Industryâ€”Sponsored Research. American Journal of Public Health, 2012, 102, 72-80.	1.5	65
124	Do Imaging Studies Performed in Physician Offices Increase Downstream Utilization?. JACC: Cardiovascular Imaging, 2011, 4, 630-637.	2.3	8
125	Use of Fibrates in the United States and Canada. JAMA - Journal of the American Medical Association, 2011, 305, 1217.	3.8	74
126	A Model for Dissemination and Independent Analysis of Industry Data. JAMA - Journal of the American Medical Association, 2011, 306, 1593.	3.8	40

#	ARTICLE	IF	CITATIONS
127	Correlation of Inpatient and Outpatient Measures of Stroke Care Quality Within Veterans Health Administration Hospitals. <i>Stroke</i> , 2011, 42, 2269-2275.	1.0	17
128	Use of Administrative Claims Models to Assess 30-Day Mortality Among Veterans Health Administration Hospitals. <i>Medical Care</i> , 2010, 48, 652-658.	1.1	15
129	Health Care Insurance, Financial Concerns in Accessing Care, and Delays to Hospital Presentation in Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1392.	3.8	121
130	Determinants of Cardiac Catheterization Use in Older Medicare Patients With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 54-62.	0.9	14
131	State-Sponsored Public Reporting Of Hospital Quality: Results Are Hard To Find And Lack Uniformity. <i>Health Affairs</i> , 2010, 29, 2317-2322.	2.5	13
132	National Patterns of Risk-Standardized Mortality and Readmission for Acute Myocardial Infarction and Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 459-467.	0.9	158
133	The relationship between systolic blood pressure on admission and mortality in older patients with heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 148-155.	2.9	41
134	Recent National Trends in Readmission Rates After Heart Failure Hospitalization. <i>Circulation: Heart Failure</i> , 2010, 3, 97-103.	1.6	373
135	Hospital Volume and 30-Day Mortality for Three Common Medical Conditions. <i>New England Journal of Medicine</i> , 2010, 362, 1110-1118.	13.9	287
136	Trends in Length of Stay and Short-term Outcomes Among Medicare Patients Hospitalized for Heart Failure, 1993-2006. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 2141.	3.8	596
137	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€“4. <i>Mayo Clinic Proceedings</i> , 2010, 85, 199-200.	1.4	0
138	Cumulative Exposure to Ionizing Radiation From Diagnostic and Therapeutic Cardiac Imaging Procedures. <i>Journal of the American College of Cardiology</i> , 2010, 56, 702-711.	1.2	166
139	Beyond insurance coverage: Usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey. <i>American Heart Journal</i> , 2010, 160, 115-121.	1.2	48
140	Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis. <i>PLoS Medicine</i> , 2009, 6, e1000144.	3.9	339
141	Reduction in Acute Myocardial Infarction Mortality in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 767.	3.8	229
142	Exposure to Low-Dose Ionizing Radiation from Medical Imaging Procedures. <i>New England Journal of Medicine</i> , 2009, 361, 849-857.	13.9	1,175
143	Regional Variation in Cardiac Catheterization Appropriateness and Baseline Risk After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 51, 716-723.	1.2	65
144	Guest Authorship and Ghostwriting in Publications Related to Rofecoxib. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1800.	3.8	398

#	ARTICLE	IF	CITATIONS
145	Use of Ezetimibe in the United States and Canada. <i>New England Journal of Medicine</i> , 2008, 358, 1819-1828.	13.9	85
146	Updated Estimates of Pharmaceutical Company Payments to Physicians in Vermont. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1998.	3.8	6
147	An Administrative Claims Measure Suitable for Profiling Hospital Performance on the Basis of 30-Day All-Cause Readmission Rates Among Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2008, 1, 29-37.	0.9	453
148	Pharmaceutical Company Payments to Physicians. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1216.	3.8	65
149	Certificate of Need Regulation and Cardiac Catheterization Appropriateness After Acute Myocardial Infarction. <i>Circulation</i> , 2007, 115, 1012-1019.	1.6	31
150	Cardiac Certificate of Need regulations and the availability and use of revascularization services. <i>American Heart Journal</i> , 2007, 154, 767-775.	1.2	23
151	Effect of Blinded Peer Review on Abstract Acceptance. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1675.	3.8	174
152	Public Misinformation and Science Communication in Times of Public Health Crises. <i>Clinical Chemistry</i> , 0, , .	1.5	0